Valproate (Depakote, Epilim)
What studies of Valproate (Depakote, Epilim) found
At a glance, by condition
Preventing long COVID: D Little or no difference
Based on the strongest evidence, compared with another group, not randomised (very low certainty), for pain.
2 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with Valproate (Depakote, Epilim) for preventing long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Valproate (Depakote, Epilim) · Preventing long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Preventing long COVID
Pain1 study · 505 people took Valproate (Depakote, Epilim) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people, or how many isn't reported.
Compared with another group, not randomised1 study · 6 months after COVID-19 diagnosis · recorded in their medications on the day of their COVID-19 diagnosis or positive PCR test for SARS-CoV-2 or within 3 months before it (few people)
No clear difference in pain.
The evidence is very uncertain about the effect of valproate (Depakote, Epilim) on pain later, when given during acute COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- Few people, or how many isn't reported
See the 1 study
-
Exposure to phenytoin associates with a lower risk of post-COVID cognitive deficits: a cohort study. (2022)
- People in the study
- —
- Dose
- recorded in their medications on the day of their COVID-19 diagnosis or positive PCR test for SARS-CoV-2 or within 3 months before it
- Outcome
- chest/throat pain
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. comparison group: propensity score-matched cohorts of patients with epilepsy taking phenytoin versus valproate or levetiracetam at the time of COVID-19 diagnosis
In total, 74 variables were used as covariates.
- Selection of participants
- Moderate. comparison group: propensity score-matched cohorts of patients with epilepsy taking phenytoin versus valproate or levetiracetam at the time of COVID-19 diagnosis
Using electronic health record data, we compared the cognitive outcomes of propensity score-matched cohorts of patients with epilepsy taking phenytoin (a commonly used receptor-interacting protein kinase inhibitor) versus valproate or levetiracetam at the time of COVID-19 diagnosis.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: not reported per arm; several patients on phenytoin did not have a level recorded during the pandemic
the total number is less than the number of individuals on phenytoin because several patients on phenytoin did not have a level recorded during the pandemic
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Moderate. a pre-specified secondary outcome
Cognition (brain fog)1 study · 505 people took Valproate (Depakote, Epilim) Uncertain –
Why this grade: Uncertain, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people, or how many isn't reported; helped less than phenytoin, an active treatment; not a sign of harm.
Compared with another group, not randomised1 study · 6 months after COVID-19 diagnosis · recorded in their medications on the day of their COVID-19 diagnosis or positive PCR test for SARS-CoV-2 or within 3 months before it (few people)
Cognition (brain fog) improved less than with the comparison treatment.
Valproate (Depakote, Epilim) helped cognition (brain fog) less than phenytoin in the one comparison. Uncertain · very low certainty –
- Serious risk of bias (ROBINS-I)
- Few people, or how many isn't reported
- Helped less than phenytoin, an active treatment; not a sign of harm
See the 1 study
-
Exposure to phenytoin associates with a lower risk of post-COVID cognitive deficits: a cohort study. (2022)
- People in the study
- —
- Dose
- recorded in their medications on the day of their COVID-19 diagnosis or positive PCR test for SARS-CoV-2 or within 3 months before it
- Outcome
- post-COVID cognitive deficits
- Effect
- worse
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. comparison group: propensity score-matched cohorts of patients with epilepsy taking phenytoin versus valproate or levetiracetam at the time of COVID-19 diagnosis
In total, 74 variables were used as covariates.
- Selection of participants
- Moderate. comparison group: propensity score-matched cohorts of patients with epilepsy taking phenytoin versus valproate or levetiracetam at the time of COVID-19 diagnosis
Using electronic health record data, we compared the cognitive outcomes of propensity score-matched cohorts of patients with epilepsy taking phenytoin (a commonly used receptor-interacting protein kinase inhibitor) versus valproate or levetiracetam at the time of COVID-19 diagnosis.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: not reported per arm; several patients on phenytoin did not have a level recorded during the pandemic
the total number is less than the number of individuals on phenytoin because several patients on phenytoin did not have a level recorded during the pandemic
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Moderate. a pre-specified primary outcome
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
250 mg at the start
- 2Top dose
Most often 250 mg (1 of 1 studies)
Doses across 1 study
250 to 250 mg.
Each study’s dose, as printed
- low dose (250 mg) 0969 Severe persistent specific sleep disorders in post-acute sequelae of SARS-CoV-2 (2023)
All papers
- Exposure to phenytoin associates with a lower risk of post-COVID cognitive deficits: a cohort study.2022 · compared with another group
Summary
This retrospective cohort study used electronic health records from TriNetX Analytics (59 healthcare organizations, primarily in the USA). It examined whether phenytoin exposure around COVID-19 diagnosis was associated with later post-COVID cognitive deficits in people with epilepsy or recurrent seizures. A total of 668 individuals with SARS-CoV-2 infection had phenytoin recorded within 3 months before or on the day of COVID-19 diagnosis; control cohorts had levetiracetam (4192 individuals) or valproate (1344 individuals). After 1:1 matching, 663 patients on phenytoin were compared with 663 on levetiracetam, and 505 on phenytoin with 505 on valproate. The outcome period was 6 months after COVID-19 diagnosis; the primary outcome was a composite of ICD-10 codes for cognitive deficits. Patients taking phenytoin were reported at significantly lower risk of post-COVID cognitive deficits than the levetiracetam cohort (HR 0.78, 95% CI 0.63–0.97, P = 0.024) and the valproate cohort (HR 0.73, 95% CI 0.58–0.93, P = 0.011). The association was sustained in the later phase of follow up (weighted log-rank P = 0.021 for levetiracetam and P = 0.026 for valproate). No significant associations were observed for other long-COVID features (all P > 0.05), except lower headache risk versus valproate (HR 0.59, 95% CI 0.38–0.93, P = 0.02), not versus levetiracetam. Therapeutic phenytoin level (n = 240) versus subtherapeutic (n = 219) gave HR 0.76, 95% CI 0.55–1.05, P = 0.091. Harms and withdrawals were not reported. The authors state the study is observational, cannot demonstrate causal effect, and residual confounding may persist.
- 0969 Severe persistent specific sleep disorders in post-acute sequelae of SARS-CoV-22023 · no comparison group · 26 with outcome data
Summary
This abstract reports an early clinical experience diagnosing and managing sleep disorders in post-acute sequelae of SARS-CoV-2 (PASC), or Long-Covid, at a dedicated Long-Covid clinic at Beth Israel Deaconess Medical Center. Twenty-six patients (age range 22 to 58 years, 16 females) with new persistent sleep impairments shortly after acute COVID-19, without pre-existing sleep impairments, were evaluated. Evaluation included polysomnography extended for hypersomnia diagnosis, Multiple Sleep Latency Test for excessive daytime sleepiness, home sleep apnea test for suspected sleep apnea, sleep logs, and a Ring oximeter-based SleepImage system. Standard management was offered based on the ensuing diagnosis. Treatment included CPAP, stimulants, modafinil, and sodium oxybate; one patient with cyclical insomnia received low dose (250 mg) sodium valproate. There was no comparison group, and duration of treatment and follow-up were not reported. The abstract reports that one patient with cyclical insomnia had a marked subjective and objective improvement with low dose (250 mg) sodium valproate. It otherwise does not report formal response rates, side effects, or withdrawals. The authors describe the work as an early experience; no formal limitations are stated.